Department of Urology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
Hematol Oncol Clin North Am. 2011 Aug;25(4):753-64. doi: 10.1016/j.hoc.2011.05.002.
Renal cell carcinoma (RCC) is considered a relatively rare malignancy worldwide. Around a third of patients with RCC present with metastatic disease, and among those patients treated with nephrectomy with curative intent, more than one-third develop metastases during postoperative follow-up. Due to the absence of curative medical treatments for metastatic RCC, surgery remains the mainstay of therapy. Surgery plays a key role in two aspects: cytoreductive nephrectomy to remove the primary renal tumor in the presence of known metastatic disease, and metastasectomy to remove distant metastatic foci in patients with metastatic RCC.
肾细胞癌(RCC)被认为是一种在全球范围内相对罕见的恶性肿瘤。大约三分之一的 RCC 患者表现为转移性疾病,而在那些接受根治性肾切除术治疗的患者中,超过三分之一的患者在术后随访期间发生转移。由于转移性 RCC 缺乏有效的治疗方法,手术仍然是主要的治疗方法。手术在两个方面发挥着关键作用:在已知存在转移性疾病的情况下进行减瘤性肾切除术以切除原发肾肿瘤,以及对转移性 RCC 患者进行转移灶切除术以切除远处转移灶。